Welch Allyn, Inc. v. iRhythm Technologies, Inc.

I'll research this case thoroughly before drafting. Let me start with the key parties, patents, and docket.

Let me dig into the IPR proceedings, the stay, and the patents' technical content.

Case Overview & Background — Welch Allyn, Inc. v. iRhythm Technologies, Inc., No. 1:24-cv-00224-MN (D. Del.)

Parties. This is a competitor-versus-competitor suit between two operating companies in ambulatory cardiac monitoring — not an NPE/PAE or university assertion. Plaintiff Welch Allyn, Inc. is a New York corporation headquartered at 4341 State Street Road, Skaneateles Falls, NY, founded in 1915 and, for over a century, a manufacturer of diagnostic equipment (its first product was the handheld direct-illuminating ophthalmoscope). Through a series of acquisitions, Welch Allyn became a subsidiary of Hill-Rom Holdings, Inc. in 2015, which in turn is now part of Baxter International Inc.; Hill-Rom also acquired Mortara Instrument (2017) and Bardy Diagnostics (2021), and Welch Allyn today markets the Bardy CAM Patch via its Bardy division. Defendant iRhythm Technologies, Inc. (NASDAQ: IRTC) is a Delaware-incorporated (Sept. 14, 2006), San Francisco–headquartered "digital health care company" that spun out of a Stanford program and sells wearable biosensor + cloud-analytics remote cardiac monitoring — the Zio platform. iRhythm restructured into a holding company (iRhythm Holdings, Inc.) effective Jan. 12, 2026. The complaint expressly pleads the two as competitors in ECG monitoring (D.I. 1 ¶ 9).

Accused technology and asserted patents. The accused products are iRhythm's Zio AT Monitor, Zio XT Monitor, and Next-Generation Zio Monitor (the latter FDA 510(k)-cleared May 21, 2021) — patches worn on the chest that record and transmit ECG data for arrhythmia detection, including AFib. Welch Allyn's asserted patents all descend from a single 2006 priority application (U.S. App. 11/591,619, filed Nov. 1, 2006) titled "Body worn physiological sensor device having a disposable electrode module." The original February 20, 2024 complaint asserted four family members — U.S. 8,214,007 ('007, issued July 3, 2012), 8,965,492 ('492, Feb. 24, 2015), 9,155,484 ('484, Oct. 13, 2015), and 10,159,422 ('422, Dec. 25, 2018). The Second Amended Complaint (D.I. 38, Feb. 14, 2025) added the two "Newly Asserted Patents" now flagged as the patents at issue: U.S. 8,630,699 ('699, issued Jan. 14, 2014) and U.S. 8,750,974 ('974, issued June 10, 2014). Technically, both claim the same body-worn monitor architecture — a physiological sensor incorporated with the monitor as a single unit non-permanently affixed to the chest, with a disposable electrode module. The '699 is a continuation of the '007 and the '974 is a divisional (via 14/103,219) directed to features such as a physically compact current-limiting defibrillation-protection resistor disposed between the electrodes/electrical connections and the ECG electronics module, so the device can survive high-energy defibrillation shocks — the historical problem the patents use to distinguish bulky, wired Holter/Micropaq-style monitors. Welch Allyn asserts at least claim 1 of the '699 and the '974 against the Zio Monitor, and claim 45 of the '007 (D.I. 38; Exs. 19, 26, 38, 39).

Procedural posture, venue, and why it matters. The case was filed in the District of Delaware, Wilmington Division, before Judge Maryellen Noreika (case flag: PATENT). Venue is essentially unchallengeable: iRhythm is a Delaware corporation and therefore "resides" in the district under 28 U.S.C. § 1400(b) post-TC Heartland, and it admitted venue and personal jurisdiction for this case (D.I. 45 ¶¶ 11, 14) — meaning Welch Allyn faced no transfer risk and got access to Delaware's deep patent bench. The docket is unusually active: an FAC (Apr. 24, 2024); a partially successful motion to dismiss willfulness that Judge Noreika granted without prejudice on Jan. 28, 2025 (Hr'g Tr.; D.I. 51), with leave to replead; the SAC adding the '699/'974; an answer (D.I. 45, Mar. 21, 2025); a Third Amended Complaint (Oct. 14, 2025) re-adding willfulness after fact discovery; and a renewed motion to dismiss those willfulness claims (Oct. 28, 2025). Fact discovery closed Jan. 16, 2026; trial was calendared for March 22, 2027. The case's notoriety, however, comes primarily from the PTAB side. iRhythm filed five IPRs on Dec. 23, 2024 (IPR2025-00363 ('422), -00374 ('492), -00376 ('484), -00377 and -00378 ('007)). On June 6, 2025, USPTO Acting Director Coke Morgan Stewart issued a Director Discretionary Decision (Paper 10) denying institution of all five — not on the merits, but as the first-ever application of the new "settled expectations of the parties" factor created by the USPTO's March 26, 2025 Interim Process for PTAB Workload Management memo. Although the traditional Fintiv factors and the expert-testimony factor cut against denial (FWD due ~Aug. 12, 2026, seven months before the district-court trial; little district-court investment; likely stay), the Director held that because iRhythm had cited the then-pending application in a 2013 IDS in one of its own applications, "[p]etitioner's awareness of Patent Owner's applications and failure to seek early review of the patents favors denial and outweighs the above-discussed considerations." The ruling drew intense practitioner commentary (IPWatchdog, Law360, Finnegan, Winston, Crowell, Dentons, Honigman) as a sea-change in IPR strategy — iRhythm's Request for Director Review (Paper 11, July 3, 2025) argued APA/due-process violations, conflict with the Director's own binding NHK precedent

I'll research this case thoroughly using web search, starting with broad queries and drilling into specific developments.

I have a strong initial picture. Let me dig into specific events: the IPRs and Director Review, the reexaminations, the stay, and the settlement.

Welch Allyn, Inc. v. iRhythm Technologies, Inc., No. 1:24-cv-00224-MN (D. Del.)

Below is a chronological reconstruction of key legal developments, drawn from the public docket (CourtListener/RECAP), iRhythm's SEC filings, PTAB papers, and law-firm/press coverage. Where a fact is not well sourced, I flag it.

Case framing

• Court/Judge: D. Del., Wilmington; assigned to Judge Maryellen Noreika (initials "MN") on 2024-02-28.
• Parties: Plaintiff Welch Allyn, Inc., a subsidiary of Hill-Rom Holdings, now part of Baxter International (Welch Allyn's Rule 7.1 disclosure identifies parents Baxter International Inc. and Hill-Rom Holdings, Inc.). Defendant iRhythm Technologies, Inc., which since a 2026-01-12 holding-company reorganization is a subsidiary of iRhythm Holdings, Inc.
• Patents asserted (final universe — six, all from the same 2006-priority family): U.S. 8,214,007 ("'007," claim 45); U.S. 8,965,492 ("'492"); U.S. 9,155,484 ("'484," claim 1); U.S. 10,159,422 ("'422," claim 1); U.S. 8,630,699 ("'699," claim 1); and U.S. 8,750,974 ("'974," claim 1). Note the two patents highlighted in the case metadata ('974 and '699) were later additions, not part of the original complaint.
• Accused products: the Zio AT, Zio XT, and Zio (Next-Generation) Monitor ambulatory ECG monitors/services.
• Counsel of record: Welch Allyn — Potter Anderson & Corroon LLP (Philip A. Rovner, P. Andrew Smith) with pro hac vice counsel (Gargano, Beane, Haulcomb, Hill, Halverson); iRhythm — Morris, Nichols, Arsht & Tunnell LLP (Brian P. Egan, Megan E. Dellinger, E. Paul Steingraber). iRhythm's PTAB filings were handled by Fenwick & West LLP.

1. Filing and initial pleadings (2024)

• 2024-02-20 — Welch Allyn filed the Complaint (Dkt. 1) asserting patent infringement and willful infringement; jury demand made. Served same day.
• 2024-03-11 — Stipulated extension of iRhythm's response deadline to 2024-04-11 (SO ORDERED).
• 2024-04-11 — iRhythm filed its Motion to Dismiss Willful Infringement Claims for Failure to State a Claim (Dkt. 9) with opening brief (Dkt. 10) and Rule 7.1 disclosure (Dkt. 11).
• 2024-04-24 — Welch Allyn filed its First Amended Complaint. iRhythm's later 10-Q disclosure states that it "successfully petitioned the District Court to dismiss the willful infringement claims without prejudice." (The precise order date/citation was not captured in my searches; treat the ruling's existence as sourced to the 10-Q, its exact date as unconfirmed.)
• 2025-01-15 — Scheduling Order entered (Dkt. 25), including: accused-product/damages identification by 2025-01-17; core technical documents by 2025-02-28; initial infringement contentions by 2025-05-08; initial invalidity contentions by 2025-07-16; **final infringement contentions by 2025

I'll research the plaintiff's counsel of record through docket records and firm sources.

Good start. Let me confirm the pro hac vice admissions and check for any additional appearances or withdrawals.

Let me verify the individual attorneys' roles, firms, and experience.

Counsel of Record for Plaintiff Welch Allyn, Inc.

Bottom line: Welch Allyn is represented by a two-tier team in D. Del. — Potter Anderson & Corroon LLP as Delaware counsel of record (the only firm that can file papers under D. Del. L.R. 83.5(d)), and K&L Gates LLP as lead/outside trial counsel, admitted pro hac vice. The same team appears in the affiliate case Bardy Diagnostics, Inc. v. iRhythm Technologies, Inc., C.A. No. 24-1355 (D. Del.) — which is why the two dockets' signature blocks look nearly identical and should not be conflated.

---

1. Delaware counsel of record — Potter Anderson & Corroon LLP

Hercules Plaza, 1313 N. Market Street, P.O. Box 951, Wilmington, DE 19899 · (302) 984-6000

Note: Rovner's local-counsel role is documented from the very first filing — he signed the Feb. 21, 2024 pro hac vice motion (D.I. 6) — and he signed the final dismissal stipulation. (CourtListener D.I. 6; CourtListener D.I. 46)

2. Lead / outside trial counsel — K&L Gates LLP (admitted pro hac vice, listed as "OF COUNSEL" on the Delaware-pleading signature blocks)

All of the above authenticated against filed signature blocks and service certifications appearing in this docket and in the related Bardy Diagnostics matter, e.g. D.I. 6 pro hac vice motion, D.I. 46 notice of appearance, D.I. 49 (Lund), D.I. 115 (Shabalov, 12/10/2025), and iRhythm's Request for Director Review service certification (listing K&L Gates attorneys as Patent Owner's PTAB counsel).

3. In-house counsel

No in-house attorney from Welch Allyn or Baxter/Hill-Rom has entered an appearance in this docket as far as the docket text and signature blocks show. That is expected in D. Del. practice, where outside Delaware counsel file all papers, and it should not be read as a finding that no in-house lawyer is working the matter behind the scenes. I found no source identifying in-house counsel, so I am not naming one.

---

Caveats and contradictions to flag

1. Case-status contradiction (material). The case metadata supplied to me says the case is "stayed." Search results indicate the case was in fact resolved: a Stipulation and Order of Dismissal — all claims and counterclaims dismissed with prejudice, each side bearing its own costs and fees — is dated August 6, 2026 and SO ORDERED August 7, 2026, signed by Rovner/Smith for Welch Allyn and Egan/Dellinger/Steingraber for iRhythm. See the Bloomberg Law copy of the stipulation (linked from the case's docket page). If accurate, the "stayed" flag in the prior sections and the metadata is stale. Recommended correction: status → dismissed with prejudice (Aug. 7, 2026), following a settlement agreement; the PTAB/IPR and willfulness threads described in the earlier sections were superseded by that resolution. (I could not retrieve the docket entry number for the stipulation in this run, so I am citing it by date and content rather than by D.I. number.)
2. Aggregator errors. DrugPatentWatch's page for this case lists "J. David Hadden" as an attorney and patents "10,029,010; 8,013,002," neither of which matches this docket — Hadden is iRhythm-side Fenwick & West counsel in the Bardy case, and those patent numbers are not the patents-in-suit here. Do not rely on that page for counsel identification. (drugpatentwatch page)
3. Unverified individual bios. I confirmed the existence and firm/office of Beane, Haulcomb, Hill, Lund, Shabalov, Moshos and Smith from filed signature blocks and service lists, but did not independently review firm bio pages for each in this run. Only Rovner, Gargano and Halverson had bio-level detail surfaced by search; treat the "experience" line items for the others as needing a firm-website check before publication.
4. Sibling case. The identical Potter Anderson + K&L Gates team also represents Bardy Diagnostics, Inc. (a Welch Allyn/Hill-Rom affiliate) against iRhythm in C.A. No. 24-1355 (D. Del.) — the two dockets share pro hac vice motions nearly word-for-word (compare Bardy D.I. 7 with Welch Allyn D.I. 6). Attribute filings to the correct case number when citing.

I'll research the defendant's counsel of record through the docket and firm sources.

Key defense-side names are emerging. Let me verify appearances on the Welch Allyn docket itself and pin down the Fenwick & West team.

Let me pin down the Fenwick team's pro hac vice admissions, the Min Wu appearance, and iRhythm's PTAB petitioner counsel.

Defendant's Counsel of Record — iRhythm Technologies, Inc.

Defendant iRhythm is represented by a two-tier team: Morris, Nichols, Arsht & Tunnell LLP as Delaware counsel of record (the only firm that signs and files in the case), and Fenwick & West LLP as out-of-state "of counsel" / lead trial counsel. This structure is repeated in the parallel Bardy Diagnostics, Inc. v. iRhythm Technologies, Inc., C.A. No. 24-1355 (D. Del.) case, where the same firms appear for iRhythm.

Delaware counsel of record — Morris, Nichols, Arsht & Tunnell LLP

1201 North Market Street, P.O. Box 1347, Wilmington, DE 19899 | (302) 658-9200

(Caveat: mid-2025 service lists in the related Bardy case also show Lucinda C. Cucuzzella of Morris Nichols for iRhythm, but I did not confirm her appearance in the Welch Allyn case.)

Of counsel / lead trial counsel — Fenwick & West LLP

These attorneys appear in the "OF COUNSEL" block of iRhythm's briefs and on the parties' service lists in this case (D.I. 31, Jan. 27, 2025; D.I. 109, Nov. 21, 2025), with a shared case-specific service address, iRhythm-WelchAllyn@fenwick.com:

PTAB side (context, not district-court counsel of record)

The prior sections of this case summary note that iRhythm's five IPR petitions (IPR2025-00363, -00374, -00376, -00377, -00378, filed Dec. 23, 2024) were handled by Fenwick & West LLP, consistent with Hadden/Wang acting as iRhythm's portfolio-wide patent counsel. I was not able to verify the individual lead/back-up counsel names on the iRhythm-side PTAB mandatory notices within the search budget for this task — flagging that as unsourced rather than guessing. (For completeness, the adverse PTAB party, patent owner Welch Allyn, is represented at the PTAB by K&L Gates: lead counsel Erik J. Halverson, back-up Anna Rebekah Hill and Jared R. Lund — that is plaintiff-side representation, listed only to avoid confusion.)

Notes, gaps, and contradictions to flag

1. No in-house counsel identified. I found no iRhythm in-house attorney admitted or noticed as counsel of record in this docket. iRhythm's in-house legal team coordinates the litigation (it is the real party in interest alongside iRhythm Holdings, Inc. post-2026 reorganization), but I could not source a named in-house lawyer appearing in this case, so I am not naming one.
2. Counsel status may be moot. Per a stipulation dated Aug. 6, 2026 and so-ordered Aug. 7, 2026, all claims and counterclaims were dismissed with prejudice by settlement, each side bearing its own fees (Bloomberg Law docket copy; Law360, Aug. 10, 2026). Morris Nichols signed for iRhythm. Practically, the appearances above are the operative ones for the case's merits phase.
3. Contradiction with the case metadata: the metadata describes the case as "stayed," and the prior Case Overview section describes it as "pending." The docket and Aug. 2026 press coverage indicate the case was stayed at some point (consistent with the IPR/re-exam posture) and then terminated by settlement dismissal with prejudice in August 2026. The docket flag "STAYED" remains on third-party docket mirrors, which likely explains the metadata. Recommend updating the metadata to "terminated — settled/dismissed with prejudice."
4. Unauthorized-practice nuance worth noting: because Fenwick & West's attorneys appear as "of counsel" on briefs rather than as Delaware counsel of record, all filings in this case are made through Morris Nichols, as required by D. Del. Local Rule 83.5(d). I confirmed pro hac vice admission orders for Welch Allyn's K&L Gates team (Gargano, Beane, Haulcomb, Hill, Halverson — D.I. 6/7, Feb. 28, 2024) but did not retrieve a corresponding PHV order for each Fenwick attorney; their admission is inferred from standard D. Del. practice and their appearance blocks, not from a document I verified.